Summary:
- Vertex Pharmaceuticals' pioneering efforts in cystic fibrosis treatment earn a prestigious award.
- Analysts predict a modest upside for Vertex Pharmaceuticals with a balanced "Outperform" rating.
- GuruFocus estimates suggest a slight downside relative to the current stock price.
Vertex Pharmaceuticals (VRTX, Financial) recently celebrated a significant achievement, as Dr. Paul Negulescu has been honored with the 2025 Canada Gairdner International Award. His visionary leadership in developing groundbreaking treatments for cystic fibrosis (CF) has greatly improved patient outcomes around the world by focusing on the genetic roots of the disease.
Wall Street Analysts Forecast
As per the analysis provided by 27 Wall Street analysts, the average one-year price target for Vertex Pharmaceuticals Inc (VRTX, Financial) is projected at $502.79. While the highest estimate reaches $615.00, the lowest sits at $330.00. This average target represents a potential upside of 3.84% from the current trading price of $484.22. For a deeper dive into these projections, visit the Vertex Pharmaceuticals Inc (VRTX) Forecast page.
Moreover, a consensus from 34 brokerage firms rates Vertex Pharmaceuticals Inc (VRTX, Financial) with an average recommendation of 2.2, signifying an "Outperform" status. This rating scale ranges from 1 to 5, where 1 indicates Strong Buy, and 5 represents Sell.
From a valuation perspective, GuruFocus estimates place the GF Value for Vertex Pharmaceuticals Inc (VRTX, Financial) at $466.84 in one year, suggesting a potential downside of 3.59% from the recent price of $484.22. The GF Value metric is an estimate of the fair value a stock should trade at, based on historical trading multiples, past business growth, and future performance forecasts. For more comprehensive data, visit the Vertex Pharmaceuticals Inc (VRTX) Summary page.
